Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: We aimed to validate the prognostic implication of uncertain resection, R(un), proposed by International Association for the Study of Lung Cancer (IASLC) and evaluate the prognostic value of spread through air spaces (STAS) in reclassifying the R classification among patients with lung adenocarcinoma after segmentectomy.

Methods: We enrolled 1007 patients who underwent segmentectomy for c-stage IA lung adenocarcinoma between 2014 and 2017. Recurrence-free survival (RFS) and overall survival (OS) were compared to evaluate the prognostic value of IASLC-R(un) and STAS. Whether STAS would skip into complementary lobectomy was evaluated in a prospective cohort.

Results: The current IASLC-R(un) failed to significantly stratify the RFS (P = .078) in segmentectomy, and STAS was a stronger risk factor of poor prognosis for both RFS and OS (P < .001). Moreover, the presence of STAS was associated with increased locoregional recurrence in patients undergoing segmentectomy (P < .001) but not in those treated with lobectomy (P = .187), indicating that only STAS-positive segmentectomy was consistent with the concept of R(un) in relapse pattern. After reclassifying STAS-positive segmentectomy into the R(un) category, the proposed R(un) showed an improvement in prognosis stratification. In addition, 2 of 30 patients (6.2%) in the prospective cohort who underwent initial segmentectomy and complementary lobectomy had STAS clusters in the complementary lobectomy specimens.

Conclusions: Unfavorable prognosis, relapse patterns consistent with R(un), and pathologic verification that saltatory spread of STAS observed in complementary lobectomy specimens supported reclassifying STAS-positive segmentectomy as R(un). STAS is a critical concern for the surgical completeness evaluation after segmentectomy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2024.03.007DOI Listing

Publication Analysis

Top Keywords

complementary lobectomy
16
lung adenocarcinoma
12
stas-positive segmentectomy
12
spread air
8
air spaces
8
evaluate prognostic
8
stas
8
segmentectomy
8
segmentectomy stas
8
reclassifying stas-positive
8

Similar Publications

Background: Lobectomy (LOB) remains the standard treatment for stage I non-small cell lung cancer (NSCLC), though sublobar resection (SLR) has emerged as a potential alternative with comparable outcomes. Spread through air spaces (STAS) has been confirmed as an independent risk factor after lung cancer surgery. The prognosis differences between LOB and SLR in patients with stage I NSCLC with STAS are controversial.

View Article and Find Full Text PDF

Background: Giant parathyroid adenoma is a rare presentation of parathyroid adenoma and can manifest only with neck mass or non-specific symptoms.

Case Presentation: In this report, a 43-year-old woman was referred to our clinic with polyuria two months ago and a neck mass with newly diagnosed stage hypertension. No additional clinical presentations were found.

View Article and Find Full Text PDF

Introduction: Congenital bronchopulmonary foregut malformations are infrequent, with less than 60 cases reported. Group 3 or esophageal bronchus involves an abnormal origin of a lobar bronchus in the esophagus.

Clinical Case: Patient with a history of heart disease requiring surgery and with left pulmonary hypoplasia.

View Article and Find Full Text PDF

Tumors located at the tracheal bifurcation constitute a heterogeneous group of neoplasms whose treatment poses significant challenges due to their anatomical location, the requirement for radical resection, the need to restore local anatomy, and the necessity of maintaining adequate oxygenation throughout the entire procedure. Advances in airway reconstruction surgical techniques, anesthesia, and complementary therapies have progressively expanded indications for radical treatment of these neoplasms, resulting in significant improvements in both short- and long-term outcomes in recent years.

View Article and Find Full Text PDF

Background: Preclinical cancer studies ascribe promising anticancer properties to metformin. Yet, clinical findings vary, casting uncertainty on its therapeutic value for non-small cell lung cancer (NSCLC) patients. We hypothesized that metformin could benefit obese and overweight patients with NSCLC.

View Article and Find Full Text PDF